– USA, MA – Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Rob Gagnon to its Board of Directors, effective December 13, 2022.
“Rob’s expertise in all areas of biopharmaceutical finance, including his ability to navigate complex business challenges, combined with his deep understanding of Verastem’s goals and operations, will be invaluable to Verastem’s work. Having worked with Rob over the past several years, I am pleased to welcome him to the Board of Directors and look forward to the input and guidance he will bring to the team,” said Lead Director, Dr. Mike Kauffman.
About Robert Gagnon
Rob Gagnon is CFO and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund and the former CBO and CFO at Verastem Oncology.
“I am committed to Verastem’s mission to deliver a new solution to patients with low-grade serous ovarian cancer and advancing the development program across RAS-driven tumors, all areas of high unmet medical need,” said Rob Gagnon. “I am excited to contribute to Verastem in this new capacity by joining the distinguished and dedicated Board of Directors and contribute to Verastem’s continued progress.”
Mr. Gagnon has more than 20 years of financial and commercial experience in heading global finance operations. Prior to his positions at Gurnet Point Capital and Verastem Oncology, he was CFO at Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine. Before this, he served as EVP, CFO, and Treasurer at Clean Harbors, Inc. as well as CAO and Controller at Biogen Idec, Inc. Earlier, he worked in various senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP.
He holds an MBA from the MIT Sloan School of Management and a Bachelor of Arts degree in accounting from Bentley College.
About Verastem Oncology
Verastem Oncology is a development-stage biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase inhibition.
For more information: https://www.verastem.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
